N,N-diethyl-2-butyne-1,4-diamine | 55111-89-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-diethyl-2-butyne-1,4-diamine
• 英文别名: N,N-diethyl-but-2-yne-1,4-diamine；N,N-diethyl-but-2-ynediyldiamine；N,N-Diaethyl-but-2-indiyldiamin；4-diethylamino-2-butynylamine；4-Diethylamino-2-butinylamin；N',N'-diethylbut-2-yne-1,4-diamine
• CAS: 55111-89-2
• 化学式: C₈H₁₆N₂
• mdl: MFCD19203830
• 分子量: 140.228
• InChiKey: IGUGEIWRQTZQPG-UHFFFAOYSA-N

物化性质

• 沸点：
  204.9±25.0 °C(Predicted)
• 密度：
  0.905±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-diethyl-2-butyne-1,4-diamine 在 氢溴酸 、 溶剂黄146 作用下， 生成 cyclohexyl-[5-(2-diethylamino-ethyl)-thiazol-2-yl]-ethyl-amine
  参考文献：
  名称：

  Ferrand; Maffrand; Eloy, European Journal of Medicinal Chemistry, 1975, vol. 10, # 6, p. 549 - 556

  摘要：

  DOI：
• 作为产物：
  描述：

  2-[4-(diethylamino)but-2-yn-1-yl]-1H-isoindole-1,3(2H)-dione 在 一水合肼 作用下， 生成 N,N-diethyl-2-butyne-1,4-diamine
  参考文献：
  名称：

  乙炔化合物具有潜在的药理价值。8.N-（4-二烷基氨基-2-丁炔基）-取代的环状酰亚胺。

  摘要：

  DOI：

  10.1021/jm00324a014

文献信息

• Agents for the Treatment of Overactive Detrusor. III. Synthesis and Structure-Activity Relationships of N-(4-Amino-2-butynyl)acetamide Derivatives.
  作者：Kazuhiko TAKE、Kazuo OKUMURA、Kazunori TSUBAKI、Takao TERAI、Youichi SHIOKAWA

  DOI：10.1248/cpb.40.1415

  日期：——

  A series of N-(4-amino-2-butynyl)acetamides were synthesized and examined for their inhibitory activity on detrusor contraction and mydriatic activity as an index of anticholinergic side effect. Among those compounds synthesized, (+)-2-cyclohexyl-N-(4-dimethylamino-2-butynyl)-2-hydroxy-2-phenylacetamide hydrochloride ((+)-13b·HCl), 2-cyclohexyl-2-hydroxy-N-(4-methylamino-2-butynyl)-2-phenylacetamide hydrochloride (13c·HCl), N-(4-dimethylamino-2-butynyl)-2, 2-diphenyl-2-hydroxyacetamide hydrochloride (14a·HCl), and 2, 2-diphenyl-N-(4-ethylamino-2-butynyl)-2-hydroxyacetamide hydrochloride (14b·HCl) showed equipotent inhibitory activity on detrusor contraction to oxybutynin (1) and less mydriatic activity. Further evaluation of these compounds as an agent for the treatment of overactive detrusor has been examined.

  合成了一系列N-(4-氨基-2-丁炔基)乙酰酰胺，并检测了其对逼尿肌收缩的抑制活性以及作为抗胆碱能副作用指标的散瞳活性。在合成的化合物中，(+)-2-环己基-N-(4-二甲氨基-2-丁炔基)-2-羟基-2-苯基乙酰酰胺盐酸盐((+)-13b·HCl)、2-环己基-2-羟基-N-(4-甲氨基-2-丁炔基)-2-苯基乙酰酰胺盐酸盐(13c·HCl)、N-(4-二甲氨基-2-丁炔基)-2,2-二苯基-2-羟基乙酰酰胺盐酸盐(14a·HCl)和2,2-二苯基-N-(4-乙氨基-2-丁炔基)-2-羟基乙酰酰胺盐酸盐(14b·HCl)在抑制逼尿肌收缩方面表现出与氧丁嗪(1)相当的活性，并且散瞳活性较低。进一步评估这些化合物作为治疗膀胱过度活动的药物的潜力。
• Novel substituted-acetamide compound and a process for the preparation
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05066680A1

  公开（公告）日：1991-11-19

  Compounds of the formula ##STR1## wherein R.sup.1 is aryl which may have one or more suitable substituent(s), R.sup.2 is aryl which may have one or more suitable substituent(s), lower alkyl or cyclo(lower)alkyl, R.sup.3 is hydrogen, hydroxy, halogen, lower alkenyl, amino or protected amino, R.sup.4 is a group of the formula: ##STR2## wherein R.sup.5 is lower alkyl which may have one or more suitable substituent(s), cyclo(lower)alkyl, aryl, ar(lower)alkyl which may have one or more suitable substituent(s), and R.sup.6 is hydrogen or lower alkyl; or N-containing heterocyclic group which may have one or more suitable substituent(s), and A is lower alkylene or lower alkynylene, in which R.sup.1 and R.sup.2 may be linked through oxygen atom, their preparation and use in treatment of dysuria, and starting materials for their preparation.

  该化合物的公式为##STR1##其中R.sup.1是芳基，可能具有一个或多个适当的取代基，R.sup.2是芳基，可能具有一个或多个适当的取代基，较低的烷基或环烷基，R.sup.3是氢，羟基，卤素，较低烯基，氨基或保护氨基，R.sup.4是以下式的基团:##STR2##其中R.sup.5是较低烷基，可能具有一个或多个适当的取代基，环烷基，芳基，芳基烷基，可能具有一个或多个适当的取代基，R.sup.6是氢或较低烷基；或含氮杂环基团，可能具有一个或多个适当的取代基，A是较低烷基或较低炔基，在其中R.sup.1和R.sup.2可以通过氧原子连接，它们的制备和在治疗排尿困难中的应用，以及它们的制备的起始材料。
• Substituted-acetamide compound and a process for the preparation thereof
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05192779A1

  公开（公告）日：1993-03-09

  Compounds of the formula ##STR1## wherein R.sup.1 is aryl which may have one or more suitable substituent(s) R.sup.2 is aryl which may have one or more suitable substituent(s), lower alkyl or cyclo(lower)alkyl, R.sup.3 is hydrogen, hydroxy, halogen, lower alkenyl, amino or protected amino, R.sup.4 is a group of the formula: ##STR2## wherein R.sup.5 is lower alkyl which may have one or more suitable substituent(s), cyclo(lower)alkyl, aryl, ar(lower)alkyl which may have one or more suitable substituent(s), and R.sup.6 is hydrogen or lower alkyl; or N-containing heterocyclic group which may have one or more suitable substituent(s), and A is lower alkylene or lower alkynylene, in which R.sup.1 and R.sup.2 may be linked through an oxygen atom, their preparation and use in treatment of dysuria, and starting materials for their preparation.

  本发明涉及一种化合物，其分子式为##STR1##其中，R.sup.1是芳基，可能具有一个或多个适当的取代基；R.sup.2是芳基，可能具有一个或多个适当的取代基，较低烷基或环状（较低）烷基；R.sup.3是氢、羟基、卤素、较低烯基、氨基或保护氨基；R.sup.4是以下式的基团：##STR2##其中，R.sup.5是较低烷基，可能具有一个或多个适当的取代基，环状（较低）烷基、芳基、ar（较低）烷基，可能具有一个或多个适当的取代基，R.sup.6是氢或较低烷基；或含氮杂环基团，可能具有一个或多个适当的取代基；A是较低的烷基或较低的炔基，在其中R.sup.1和R.sup.2可以通过氧原子连接。本发明还涉及其制备方法、用于治疗尿路疾病的用途以及其制备的起始材料。
• A novel substituted-acetamide compound and a process for the preparation thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0383256A2

  公开（公告）日：1990-08-22

  A substituted-acetamide compound of the formula : wherein R1 is aryl which may have one or more suitable substituent(s), R2 is aryl which may have one or more suitable substituent(s), lower alkyl or cyclo(lower)alkyl, R3 is hydrogen, hydroxy, halogen, lower alkenyl, amino or protected amino, R4 is a group of the formula : wherein R5 is lower alkyl which may have one or more suitable substituent(s), cyclo(lower)alkyl, aryl, ar(lower)alkyl which may have one or more suitable substituent(s), and R6 is hydrogen or lower alkyl; or N-containing heterocyclic group which may have one or more suitable substituent(s), and A is lower alkylene or lower alkynylene, in which R1 and R2 may be linked through oxygen atom, and a pharmaceutically acceptable salt thereof, processes for their preparation and pharmaceutical compositions comprising them as an active ingredient. The invention relates also to intermediates of the above formula, wherein R4 is a leaving group.

  式中的取代乙酰胺化合物 其中 R1 是芳基，可以有一个或多个合适的取代基、 R2 是芳基（可带有一个或多个合适的取代基）、低级烷基或环（低级）烷基、 R3 是氢、羟基、卤素、低级烯基、氨基或受保护氨基、 R4 是式中的基团： 其中 R5 是可具有一个或多个合适取代基的低级烷基、环（低级）烷基、芳基、可具有一个或多个合适取代基的芳基（低级）烷基，和 R6 是氢或低级烷基； 或含 N 的杂环基团，可具有一个或多个合适的取代基，且 A 是低级亚烷基或低级亚炔基、 其中 R1 和 R2 可通过氧原子连接，及其药学上可接受的盐、其制备工艺和包含它们作为活性成分的药物组合物。本发明还涉及上式的中间体，其中 R4 为离去基团。
• Wille et al., Justus Liebigs Annalen der Chemie, 1955, vol. 591, p. 177,186
  作者：Wille et al.

  DOI：——

  日期：——